Study of TG02 Citrate in Patients With Advanced Hepatocellular Carcinoma
This is a single-centre, open-label, dose escalation, Phase 1 study. The primary objective is to determine the highest dose of TG02 citrate that can safely be given to patients with advanced hepatocellular carcinoma.
Hepatocellular Carcinoma
DRUG: TG02 Citrate
Maximum Tolerated Dose, To assess the number of patients with dose-limiting toxicities (DLT) and the dose of TG02 citrate that can be safely given to patients with advanced hepatocellular carcinoma., 28 days
Adverse Event, All adverse events will be graded according to NCI-CTCAE, Version 4, up to 12 months|Objective Response Rate, with respect to RECIST version 1.1, Proportion of patients, whose best overall response is either Complete Response or Partial Response, confirmed at least 4 weeks after initial documentation., Up to 12 months|Progression Free Survival, At progression, up to 12 months|Overall Survival, At death, up to 12 months
Molecular Marker, Correlation of molecular marker, c-MYC, with measures of clinical benefit., At baseline
This is a single-centre, open-label, dose escalation, Phase 1 study. The primary objective is to determine the highest dose of TG02 citrate that can safely be given to patients with advanced hepatocellular carcinoma.